Objective: To determine the prevalence of diabetic peripheral neuropathic pain (DPNP) among South African adults with type 1 or type 2 diabetes. Methods: This cross-sectional study recruited patients with diabetes from 50 institutional/private clinics. DPNP was diagnosed using Douleur Neuropathique 4 (DN4) questionnaire (score !4).
Introduction
Diabetic peripheral neuropathy (DPN) is the most common complication of diabetes mellitus, affecting up to 50% of patients. 1 DPN is associated with significant morbidity and mortality, and is a very common cause of non-traumatic amputations and hospital admissions as well as increased healthrelated costs. 1 Up to 11% of patients with DPN may be affected by diabetic peripheral neuropathic pain (DPNP), 2 defined by the International Association for the Study of Pain as pain arising as a direct consequence of abnormalities in the peripheral somatosensory system, in people with diabetes. 3 Clinically, DPNP is characterized by pain of insidious onset, which is described as burning, shooting or aching. It may be accompanied by allodynia, hyperalgesia and numbness, with symptoms often worsening at night. 2 While hyperglycaemia and longstanding diabetes are known risk factors for DPN 2, 4 the association of these factors with DPNP has not been established. 2 DPNP responds poorly to conventional analgesics such as nonsteroidal anti-inflammatory drugs (NSAIDs) 1 and may lead to sleep disruption and depression, and may interfere with daily activities. Consequently, DPNP is associated with significant deterioration in patients' healthrelated quality-of-life (HRQoL). 2 Despite the high comorbidity associated with DPNP, its epidemiology has not been adequately researched. Existing studies include heterogeneous populations and use different methods for defining and estimating DPNP, and prevalence estimates range between 10% and 65%. 2, [5] [6] [7] [8] [9] While numerous studies have assessed the prevalence of DPN, many do not report the prevalence of DPNP. 5 Furthermore, studies show that DPNP is underdiagnosed and undertreated. 9, 10 The prevalence of diabetes in South Africa is unknown. According to the International Diabetes Federation, 11 it was estimated to be 7.04% in 2012 (approximately 3.5 million of a total population of around 52 million 12 ), with over 1.5 million people having undiagnosed diabetes. Thus, a large proportion of the South African population may be susceptible to DPNP, but there are scarce data on the epidemiology of DPNP in South Africa.
The primary objective of the present study was to determine the prevalence of DPNP among adults with type 1 or type 2 diabetes mellitus, seeking treatment at private and institutional outpatient clinics in South Africa. The secondary objectives were to assess their HRQoL and sleep, and identify the most common types of drugs taken for pain, the most common types of diabetes complications and concurrent diagnoses. An exploratory objective was to identify clinical and demographic factors associated with the presence of neuropathic pain.
Patients and methods

Study population and design
This cross-sectional, descriptive study aimed to enrol 1000 patients with diabetes from 50 institutional and private outpatient clinics located across South Africa. Study centres were selected from Pfizer RightTrack investigator/site database, according to their past clinical trial performance in Pfizer trials. After feasibility, unresponsive sites were dropped and more sites were added from other large provinces such as Gauteng. People attending outpatient clinics in eight of the nine South African provinces were enrolled in the study; no participants were enrolled from Limpopo province. The study chronologically enrolled the first 20 people attending the outpatient clinics of the selected centres between June 2011 and December 2011. Inclusion criteria were: (i) confirmed diagnosis of type 1 or 2 diabetes; (ii) aged !18 years; (iii) provided a signed and dated consent form. Participants were excluded if they had mental or any other disorders considered likely to affect the reliability of their responses, and/or if they had neuropathic pain of nondiabetic origin (such as postherpetic neuralgia, diffuse pain [fibromyalgia], phantom pain, or pain due to cancer, radiculopathy, spinal cord injury, multiple sclerosis, carpal tunnel syndrome or trigeminal neuralgia).
The study was conducted in compliance with the Declaration of Helsinki and International Conference on Harmonization Good Clinical Practice Guidelines. Written informed consent was obtained from each participant. The protocol was approved by the Institutional Review Board and Independent Ethics Committee of Pharma-Ethics, and Medunsa Research and Ethics Committee of the University of Limpopo, South Africa.
Outcome measures
Diagnosis of DPNP was made by a score of !4 on Douleur Neuropathique 4 (DN4), a physician-administered questionnaire developed and validated for identifying patients with neuropathic pain. 13 The DN4 score was derived by counting the number of positive responses to each of the 10 items of the questionnaire, including burning, painful cold, electric shocks, tingling, pins and needles, numbness, itching, hypoesthesia to touch, hypoesthesia to prick, and brushing. Only those who answered all 10 questions of the DN4 questionnaire were included in the analysis for estimating the prevalence of DPNP.
Trained study investigators used a Case Report Form (CRF) to anonymously record patients' basic demographic (age, sex, race and employment status) and clinical data (height, weight, body mass index [BMI], smoking status, medical and treatment history). HRQoL was assessed with EQ-5D, a standardized instrument that uses the domains of mobility, self-care, usual activities, pain/discomfort and anxiety/depression to calculate the overall score (1, perfect health; 0, dead). 14 Interference of sleep due to pain was assessed with the Daily Sleep Interference Scale (DSIS) on a 0-10 scale (0, pain did not interfere with sleep; 10, pain completely interfered with sleep) validated for assessing the quality of sleep in people with DPNP. 15 
Statistical analyses
Descriptive statistics were used to summarize continuous data (median [range], or mean AE SD) and categorical data (n [%]). Binary variables were further described using 95% confidence intervals (CI). The association of clinical and demographic factors (explanatory variables) with the presence of DPNP (outcome variable) was evaluated in two steps. First, the univariate association of clinical and demographic factors with the presence of DPNP was examined using 2 -test. Next, stepwise multiple logistic regression analyses were performed to evaluate the independent association of explanatory variables with the presence of DPNP. Odds ratios (OR) and 95% CI were presented for each category of the selected explanatory variables. P-values 0.05 were defined as statistically significant. All data were analysed using SAS Õ version 9.2 (SAS Institute, Cary, NC, USA).
Results
A total of 1046 patients participated in the study (535 male/510 female; mean age 55.9 AE 13.1 years). Of these, 1036 completed the study. Reasons for discontinuation included failure to meet eligibility criteria (n ¼ 2) and incomplete CRFs (n ¼ 8). Demographic and clinical characteristics of the study population as a whole, and of those who completed the DN4 questionnaire, are shown in Table 1 .
The DN4 questionnaire was completed by 961 patients. The prevalence of DPNP (DN4 score ! 4) was 30.3% (291/961; 95% CI 27.4, 33.2). The prevalence of DPNP in the total study population (regardless of completion of DN4 questionnaire) was 27.8% (291/1046; 95% CI 25.1, 30.5). A majority of the patients were recruited from private clinics (n ¼ 1021). Of these, 939 completed the DN4 questionnaire and 284 (30.2%) were diagnosed with DPNP. Only 25 patients were recruited from institutional clinics, 22 of whom completed the DN4 questionnaire and seven of whom (31.8%) were diagnosed with DPNP. Univariate analysis revealed that age, sex, race and duration of diabetes were significantly associated with DPNP (P 0.05 for each comparison, Table 1 Table 2) .
Prior or concomitant pain control treatment was reported by 1041/1046 patients (99.5%; Table 3 ); the CRF did not record whether the medications were self-or physician-prescribed. Overall, 453 patients (43.3%) took at least one drug for pain, and 95 (9.1%) took a medication with proven efficacy to control DPNP, such as anticonvulsants, opioids, serotonin-norepinephrine reuptake inhibitors (SNRIs) and tricyclic antidepressants (TCAs). 16 The most frequently reported concomitant pain medications belonged to the NSAID class (n ¼ 363) ( Table 3 ). The most common drugs taken for pain included acetylsalicylic acid (n ¼ 322), amitriptyline (n ¼ 27) and pregabalin (n ¼ 26).
Data regarding diabetes complications and concurrent diagnoses are shown in Table 4 . The most commonly reported diabetes complications were erectile dysfunction (213/529; 40.3%, diabetic retinopathy (123/1028; 12.0%) and diabetic nephropathy (113/1029; 11.0%). Concurrent diagnoses such as dyslipidaemia and hypertension were reported by 528/1033 (51.1%) and 755/1041 (72.5%) of patients, respectively.
Data regarding EQ-5D scores are given in 
Discussion
The current cross-sectional study found a 30.3% prevalence of DPNP among patients with type 1 or type 2 diabetes attending outpatient clinics across South Africa. This rate aligns with prevalence data from other epidemiological studies conducted in the UK, neither of which assessed pain via DN4. 5, 6 A study in Belgium that used Neuropen Õ (Owen Mumford, Oxford, UK) and DN4 to evaluate DPNP found a prevalence of 14% in the diabetic population. 9 The prevalence of DPNP in our study was lower than that found in five Middle Eastern countries (53.7%) 8 and Saudi Arabia (65.3%), 7 both of which were studies that used DN4. The high DPNP prevalence in Saudi Arabia was attributed to poor glycaemic control. 7 The most frequently reported DPNP symptoms in the present study included burning, pins and needles and numbness, which are considered to be classic symptoms of DPNP. 1, 2 In accordance with the findings of others, 7, 8 patients in the present study who had diabetes for !10 years had a 55% increased risk for DPNP, suggesting that this may be an important risk factor. In addition, there was a 71% increased risk of DPNP in participants aged 50-64 years versus those aged <50 years. Others have found that age >53 years 7 or >50 years 8 was a significant predictor of DPNP. Similar to findings of studies from the UK and Middle East, 5,8 female patients had a 59% higher risk for DPNP than male patients in the present study.
The present study included a large proportion of black patients (291/1046; 27.8%), who were found to have a 71% higher risk of DPNP than white patients. These data will improve the understanding of the epidemiology of DPNP in this demographic group, information on which has so far been limited. A potential confounding factor could be a relatively high rate of HIVrelated neuropathy in this group, as there is known to be a high prevalence of HIV seropositivity in the black South African population. 17 It is possible that the high DPNP prevalence is due to the inclusion of patients with HIV-related neuropathy, 18 but HIV testing was not performed in the present study. A significantly increased risk of DPNP was found among South Asians in the UK, 5 but others have shown no statistically significant association between racial origin and DPNP prevalence in the Middle East (although this study only included 87 black patients). 8 A large proportion (34.6%) of patients in the present study reported taking NSAIDs for pain control, but these drugs have no efficacy in relieving DPNP. 1 In addition, long-term NSAID use in diabetic patients can lead to adverse events such as impaired renal function and gastrointestinal bleeding, particularly in the elderly. 19 In contrast, few patients (9.1%) in the current study reported taking medications with proven efficacy for reducing neuropathic pain (such as anticonvulsants, opioids, SNRIs or TCAs). Opioids are proven to reduce DPNP, 20 but should be used with caution due to adverse events such as sedation, constipation and rebound headache. Moreover, chronic opioid use can lead to tolerance and dose escalation. 20 It is clear that DPNP is inadequately treated in South Africa and measures to improve the diagnosis and management of this condition are warranted. Similar observations were made in other studies. Daousi et al. 10 evaluated the prevalence of chronic painful peripheral neuropathy (CPPN) in patients with diabetes in a community in Liverpool, UK, and found that 12.5% of patients had never reported their symptoms to their physicians and 39.3% had never received any treatment for their pain. Similarly, Van Acker et al. 9 found that only half of their study patients were receiving treatment for pain, and of these only 28% were prescribed anticonvulsants or antidepressants while >40% were prescribed ineffective treatments such as NSAIDs, paracetamol and weak opioids.
Patients with DPNP were more likely to report problems with mobility and performing usual activities than those without DPNP in the current study, which may account for their lower HRQoL scores. These findings are in accordance with those from other epidemiological studies, where diabetic people with chronic painful peripheral neuropathy (CPPN) were found to have significantly higher median pain disability index scores than those without CPPN. 10 Another study determined that patients with DPNP had significantly poorer HRQoL than those without pain. 6 The present study has several strengths. To our knowledge, it is the first large community study evaluating the prevalence of DPNP in South African patients with diabetes. The study enrolled patients from clinics located in eight of the nine South African provinces, and included both private and public outpatient clinics. We therefore believe that this cohort represents a good selection of patients from varied geographical locations and socio-economic backgrounds. In addition, we have demonstrated that DN4 is an easy-to-use and reliable screening tool for DPNP in diabetes. It is hoped that our findings will encourage practitioners to routinely use DN4 for DPNP screening in their patients with diabetes and, consequently, improve their management and HRQoL.
The present study has several limitations. First, glycaemic control was not evaluated. Studies have shown that hyperglycaemia is closely associated with DPN and, possibly, also DPNP. 1, 4 The Diabetes Control and Complications Trial Research Group showed that intensive therapy to maintain glucose concentrations as close to normal as possible was effective in delaying the onset and slowing the progression of DPN. 21 Thus, control of hyperglycaemia forms an important component of DPNP management. 1, 15, 22 Secondly, the severity of pain was not evaluated, although the majority of patients both with and without pain responded that 'pain had no effect on their employment status'. Data regarding pain severity may have served to further improve the understanding of the impact of pain on HRQoL, sleep disturbance and employment status. Finally, other possible causes of painful neuropathy in the study population (such as vitamin B12 deficiency, HIV seropositivity and alcoholism) were not investigated.
In conclusion, there is a high prevalence of DPNP in South African patients with diabetes. Patients with neuropathic pain have poorer HRQoL and sleep than those without pain. Early detection and appropriate treatment of DPNP with medications of proven efficacy are important in improving the HRQoL of patients with DPNP. 23 The American Diabetes Association, thus, recommends screening patients with diabetes for DPN at diagnosis and at least annually thereafter, using simple clinical tests. 23 DN4 is an easy-touse, validated questionnaire that can be used widely as a DPNP screening tool in clinical practice. 
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